HALO

Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.

Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

For questions about this article or underlying research, email [email protected].

Renaissance Investment Management, an investment management company, released its Q3 2026 investor letter for “Large Cap Growth Strategy.” The letter can be downloaded here. Stocks showed modest gains in Q3, with the S&P 500 up 2.3%.

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with under-the-skin shots

Halozyme Therapeutics has been on fire lately. In the past six months alone, the company’s stock price has rocketed 73.5%, reaching $120.69 per share.

On 6 October 2026, Halozyme Therapeutics reported that argenx expanded its global collaboration and license agreement, adding two more exclusive ENHANZE targets, with Halozyme eligible for milestones and royalties on future net sales that use the platform.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.